The start of a Phase II trial of an MDI formulation of ensifentrine in COPD is in line with expectations, and follows positive singledose Phase II data on the DPI formulation (announced in early March). We stress that positive results from trials of handheld inhaler versions of ensifentrine (MDI and/or DPI) could open the door to the very large market, addressable in collaboration with a strategic partner. Over 5m patients in the US alone use handheld inhalers for the maintenance treatment of CO ....
04 Jun 2019
Phase II start of MDI ensifentrine heralds potential market expansion
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Phase II start of MDI ensifentrine heralds potential market expansion
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
04 Jun 2019 -
Author:
Jens Lindqvist -
Pages:
3
The start of a Phase II trial of an MDI formulation of ensifentrine in COPD is in line with expectations, and follows positive singledose Phase II data on the DPI formulation (announced in early March). We stress that positive results from trials of handheld inhaler versions of ensifentrine (MDI and/or DPI) could open the door to the very large market, addressable in collaboration with a strategic partner. Over 5m patients in the US alone use handheld inhalers for the maintenance treatment of CO ....